CEREVEL STOCK UPDATE: Is $45 Per Share Enough for Cerevel (Nasdaq:CERE)? Contact BFA Law about Ongoing Investigation into the Deal Price

Claim Details: BFA is currently investigating the go private transaction and believes that Cerevel Therapeutics' board of directors was conflicted, engaged in an unfair process, and agreed to an unfair amount to be paid to shareholders. If you are a current shareholder, you are encouraged to submit your information to find out about your rights. Next Steps: All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigatio ...